Screener
Krystal Biotech, Inc. KRYS Available For Sale Securities Debt Securities Current
Available For Sale Securities Debt Securities Current at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $501,313 | $496,304 |
| Short-term investments | 322,092 | 331,487 |
| Accounts receivable, net | 127,022 | 127,425 |
| Inventory | 42,646 | 40,475 |
| Prepaid taxes | 10,642 | 14,006 |
| Prepaid expenses and other current assets | 16,026 | 14,905 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s available for sale securities debt securities current?
- Krystal Biotech, Inc. (KRYS) reported available for sale securities debt securities current of $322.09M in Q1 2026.
- How has Krystal Biotech, Inc.'s available for sale securities debt securities current changed year-over-year?
- Krystal Biotech, Inc.'s available for sale securities debt securities current increased by 4.5% year-over-year, from $308.08M to $322.09M.
- What is the long-term trend for Krystal Biotech, Inc.'s available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s available for sale securities debt securities current has grown at a 156.4% compound annual growth rate (CAGR), from $2.99M to $331.49M.
Ask your AI about Krystal Biotech, Inc.'s available for sale securities debt securities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude